Attached files
| file | filename |
|---|---|
| EX-10.22 - EXHIBIT 10.22 - Targeted Medical Pharma, Inc. | v243899_ex10-22.htm |
| EX-10.25 - EXHIBIT 10.25 - Targeted Medical Pharma, Inc. | v243899_ex10-25.htm |
| EX-10.23 - EXHIBIT 10.23 - Targeted Medical Pharma, Inc. | v243899_ex10-23.htm |
| EX-10.26 - EXHIBIT 10.26 - Targeted Medical Pharma, Inc. | v243899_ex10-26.htm |
| EX-10.24 - EXHIBIT 10.24 - Targeted Medical Pharma, Inc. | v243899_ex10-24.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): December 28, 2011
|
TARGETED MEDICAL PHARMA, INC.
|
|
(Exact name of registrant as specified in its charter)
|
|
DELAWARE
|
000-53071
|
20-5863618
|
||
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
2980 BEVERLY GLEN CIRCLE, SUITE 301
|
|
LOS ANGELES, CA 90077
|
|
(Address of principal executive offices)
|
|
(310) 474-9808
|
|
(Registrant’s telephone number, including area code)
|
|
Not Applicable
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Explanatory Note:
This Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed on February 3, 2011 in connection with our confidential treatment request by pursuant to 17 C.F.R. Sections 200.8(b)(4) and 240.24b-2. This Form 8-K/A includes Exhibits 10.22 through 10.26 with those redactions approved by the Securities and Exchange Commission in our confidential treatment request.
Forward Looking Statements
This Form 8-K and other reports we file from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward looking statements and information that are based upon beliefs of, and information currently available to, our management as well as estimates and assumptions made by our management. When used in the filings the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" or the negative of these terms and similar expressions as they relate to us or our management identify forward looking statements. Such statements reflect our current view with respect to future events and are subject to risks, uncertainties, assumptions and other factors (including the risks contained in the Filings) relating to our industry and our operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.
Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements and except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part of this amended current report on form 8-K/A.
* 10.22 Agency Agreement, dated March 29, 2010, by and between Targeted Medical Pharma, Inc. and Biomatrix Pharma.
* 10.23 Purchase Agreement, dated April 7, 2010, by and between Targeted Medical Pharma, Inc. and Global Med Management LLC.
* 10.24 Purchase Agreement, dated October 20, 2008, by and between Targeted Medical Pharma, Inc. and Global Med Management LLC.
* 10.25 Purchase Agreement, dated February 13, 2008, by and between Targeted Medical Pharma, Inc. and Pacific Medical, Inc.
* 10.26 Fulfillment Services Agreement, dated October 2, 2008, by and between Targeted Medical Pharma, Inc. and H.J. Harkins Co., Inc. d/b/a Pharma Pac.
*Certain terms and provisions of this exhibit have been redacted in accordance with the approval of our confidential treatment request pursuant to 17 C.F.R. Sections 200.8(b)(4) and 240.24b-2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
| TARGETED MEDICAL PHARMA, INC. | ||
|
/s/ William Shell
|
||
|
William Shell
|
||
|
Chief Executive Officer
|
||
Dated: December 28, 2011